LingVo.club
📖+20 XP
🎧+15 XP
+25 XP
Experimental drug protects hearts in Duchenne muscular dystrophy (Level A2) — refill of liquid on tubes

Experimental drug protects hearts in Duchenne muscular dystrophyCEFR A2

17 Jul 2026

Adapted from U. South Florida, Futurity CC BY 4.0

Photo by Louis Reed, Unsplash

Level A2 – High beginner / Elementary
2 min
112 words

Duchenne muscular dystrophy (DMD) is a genetic disease that weakens muscles and often affects the heart. Heart disease is a leading cause of serious illness in people with DMD.

A study published in Molecular Therapy tested the experimental drug Setanaxib in two preclinical models of DMD. The treatment preserved cardiac function, limited heart enlargement and reduced tissue scarring. The findings also point to the enzyme NOX4 as a possible target for future treatments of cardiomyopathy, a serious heart condition linked to DMD.

Setanaxib works to limit oxidative stress and lowered inflammation and fibrosis in the models. The researchers hope the drug will be tested soon in clinical trials for people with DMD.

Difficult words

  • geneticRelating to genes and inherited from parents
  • enzymeA protein that helps chemical reactions in body
  • cardiomyopathyA disease of the heart muscle causing weakness
  • inflammationBody reaction that causes redness and swelling
  • fibrosisThick or scar tissue that forms in organs
  • preclinicalBefore tests in people; in lab or animals

Tip: hover, focus or tap highlighted words in the article to see quick definitions while you read or listen.

Discussion questions

  • How could a drug that protects the heart help people with DMD?
  • What would you want to know before trying a new drug in a clinical trial?
  • Why is it important to test a drug first in models before people?

Related articles

Tofersen slows a rare form of ALS (Level A2)
26 Dec 2025

Tofersen slows a rare form of ALS

A long-term study shows that tofersen, a drug for a rare genetic form of ALS, can slow disease progression and help some people improve. The trial followed participants for several years and recorded benefits and side effects.